FTC greenlights $20B GE-Danaher deal

By The Science Advisory Board staff writers

March 20, 2020 -- Following an agreement with the U.S. Federal Trade Commission (FTC), GE Healthcare Life Sciences is moving forward with the sale of its GE Biopharma business to Danaher for $20 billion as planned.

The two companies entered into a consent decree agreement with the FTC regarding the deal, which is expected to close on March 31.

Danaher's acquisition of GE Biopharma was announced in February. At the time, the company said it planned to establish the GE division as a standalone operating company within its $6.5 billion life sciences segment, which includes Beckman Coulter Life Sciences.

The European Commission and antitrust authorities in Brazil, China, Israel, Japan, Korea, and Russia also have cleared the transaction, according to the companies.

Biopharma processing market shows early indicators of strong 2020
The biopharmaceutical processing market shows early indicators of strong 2020, according to our partners Strategic Directions International and Kalorama...
Thermo Fisher set to acquire Qiagen after all in $11.5B deal
After an on-and-off courtship, Thermo Fisher Scientific announced it is set to acquire Qiagen in a deal worth $11.5 billion. The transaction will...
GE & Advanced Solutions announce strategic collaboration
On Sunday, December 8, GE Healthcare Life Sciences and Advanced Solutions Life Sciences announced a strategic partnership for their integrated IN Cell...
GE launches super-resolution microscope
GE Healthcare announced the newest addition to their collection of microscopes, the DeltaVision OMX Flex super-solution microscope, on September 18. EDGE...
Is It Worth The Risk? Business Trends You Should Know About In The Bioprocessing Industry
The bioprocessing market is currently worth billions of dollars globally and is expected to increase 8.7 percent over the next five years. Pharmaceutical...
The Breakthrough World of Bioprocessing
Biomanufacturing instruments and techniques have become influential in everything from generating high yield pharmaceutical precursors, to biofuel conversion...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter